BREAKING NEWS

S.Korea's Celltrion gets UK approval for trials of COVID-19 antibody drug

SEOUL, July 30 - South Korea's Celltrion Inc on Thursday said British regulators had given it regulatory approval for a phase I clinical trial of its experimental COVID-19 treatment drug.
The company will enroll participants for a clinical study in the UK after approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), Celltrion said in a statement.
South Korean regulators on July 17 approved an early stage clinical trial for the drug, making it the country's first such antibody drug to be tested on humans.


Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use